New drug combo targets tough pancreatic cancer in early trial
Disease control
Ongoing
This early-phase study tests a new drug called OMO-103, which blocks a cancer-driving protein called MYC, combined with standard chemotherapy in 26 people with metastatic pancreatic cancer who have not had prior treatment for advanced disease. The main goals are to check safety a…
Phase: PHASE1 • Sponsor: Peptomyc S.L. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC